Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer

Bhuvaneswari Ramaswamy, Ewa Mrozek, John Philip Kuebler, Tanios Bekaii-Saab, Eric H. Kraut

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases 1 and 2. We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental Design: In this phase II multicenter study, patients who were treated with no more than one prior chemotherapy for MBC were treated with 750 mg/m2 of PZA given as a 3 hour intravenous infusion every 3 weeks. Treatment cycles were continued until disease progression or unacceptable toxicities. The study was designed to distinguish between a response rate of <15% vs >30% (alpha=0.10, beta=0.10) using Simons optimal 2-stage design. At least 2 responses were required in the first 12 patients in the 1st stage and 6 of 35 in the 2nd stage to recommend the agent for further study. Results: Two patients in the first stage had a response allowing accrual to second stage. A total of 15 patients (out of 35 planned) were treated on the study prior to premature closure. Three patients had a partial response (20%) lasting 4.5-6 months. Two patients had stable disease for 3 and 5 months. The dose limiting toxicity was granulocytopenia with ten patients requiring dose reduction or dose delay for grade 4 neutropenia. Other grade 3 and 4 toxicities include vomiting (n=2), nausea (n=2), neurotoxicity (n=1), fatigue (n=1), anemia (n=1), dyspnea 9n=1) and renal (n=1). Conclusions: Pyrazoloacridine demonstrated modest activity in patients with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)347-351
Number of pages5
JournalInvestigational New Drugs
Volume29
Issue number2
DOIs
StatePublished - Apr 1 2011

Keywords

  • Metastatic breast cancer
  • Phase II
  • Pyrazoloacridine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this